“Bullish on Piramal Pharma, recommending a buy at ₹172–176 with a target of ₹188 and a stop-loss at ₹167. After five quarters of underperformance, the stock is forming a higher base above a falling trendline breakout, with a bullish crossover in the weekly stochastic oscillator confirming a resumption of the uptrend and a positive bias.”

Dharmesh Shah’s track record: 6 graded calls · 95% CI 30–90%